GeoVax Advances GEO-MVA Pivotal Study and Reports Q2 2026 Results

GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company, has announced its second quarter 2026 financial results and provided a business update highlighting progress toward the pivotal GEO-MVA immunobridging study. The study, planned for Q4 2026, aims to demonstrate non-inferiority to an approved MVA vaccine under an expedited regulatory pathway established with the European Medicines Agency (EMA). CEO David A. Dodd emphasized the importance of this milestone, stating that GEO-MVA could address the growing global need for diversified MVA vaccine supply for public health preparedness and biodefense. The company is also advancing its Gedeptin immuno-oncology program, which targets solid tumors by enhancing immune checkpoint inhibitor therapy, such as Merck's Keytruda.

During the quarter, GeoVax executed clinical planning, manufacturing preparation, and engaged with government and biodefense stakeholders. The company has already manufactured cGMP clinical trial material and is advancing the AGE1 continuous cell-line manufacturing platform for future commercial-scale production. GeoVax believes GEO-MVA is uniquely positioned to help address the need for diversified global MVA vaccine manufacturing capacity, supporting public health preparedness and biodefense resilience. The Gedeptin program is being advanced toward combination immunotherapy strategies, leveraging an exclusive intellectual property license from Emory University.

Financially, GeoVax reported a net loss of $4.4 million for Q2 2026, compared to $5.4 million in Q2 2025. The decrease was primarily due to lower R&D expenses following the discontinuation of the GEO-CM04S1 COVID-19 vaccine program, which was terminated by BARDA. The company ended the quarter with $3.1 million in cash. GeoVax is prioritizing resources toward GEO-MVA and Gedeptin, which offer clearer regulatory pathways and stronger commercialization potential. The company's strategic focus includes executing the pivotal immunobridging study, advancing scalable manufacturing, and engaging in government procurement opportunities. For more information, visit www.geovax.com.